Abstract
Background
There is no information about HRQoL, depression and associated factors in adult with nephrotic syndrome-associated glomerulopathy.
Methodology/Principal Findings
Patients with primary glomerulopathy where compared with age and sex-matched hemodialysis patients and healthy subjects. Laboratory data, medical history, comorbid conditions were collected to evaluate factors associated with HRQoL (SF-36) and Depression (Hamilton Depression Rating Scale - HAMD). Glomerulopathy patients had low HRQoL in all eight SF-36 domains and two composite scores (physical and mental) in comparison with healthy subjects. HAMD score also was elevated and there was high depression prevalence. Overall, these data were comparable between glomerulopathy and hemodialysis patients. Using multiple regression analysis, factors associated with low HRQoL physical composite score were: last 24 h-urine protein excretion (−0.183, 95%CI −0.223 to −0.710 for each gram of proteinuria, p = 0.01) and cyclosporine use (−15.315, 95%CI −25.913 to −2.717, p = 0.03). Low HRQoL mental composite score was associated with last 24 h-urine protein excretion (−0.157, 95%CI −0.278 to −0.310 for each gram of proteinuria, p = 0.03) and HMAD score was independently associated with age (0.155, 95%CI 0.318 to 0.988 for each year, p = 0.04), female sex (4.788, 95%CI 1.005 to 8.620, 0 = 0.03), disease duration (0.074, 95%CI 0.021 to 0.128 for each month, p = 0.01) and last 24 h-urine protein excretion (0.050, 95%CI 0.018 to 0.085 for each gram of proteinuria, p = 0.02).
Conclusions/Significance
Nephrotic-syndrome associated glomerulopathy patients have low HRQoL and high prevalence of depression symptoms, comparable with those of hemodialysis patients. Last 24 h-protein excretion rate is independently associated with physical and mental HRQoL domains in addition to depression.
Introduction
Glomerulopathy is a group of diseases that affect mainly young adults between 20–40 years old [1]. Patients with nephrotic syndrome generally present with important edema, lipid alterations, hypoalbuminemia, and possible loss of renal function. Moreover, treatment involves dietary restrictions and immunosuppression therapy with their adverse effects. All these factors can potentially affect health-related quality of life (HRQoL). Many nephrotic syndrome features are related to a worse HRQoL: protein-nutrition alteration [2], lipid metabolism alteration [3] and reduced glomerular filtration rate (GRF) [4].
Depression is common in general medical patients, with female prevalence of 5 to 9% and 2 to 3% in men [5]. Depression is thought to be associated with worse general health status [6] and is associated with several chronic diseases [7], [8], including chronic Kidney disease (CKD) [9]. In some populations, screening in some special population, such as those undergoing renal replacement therapy, is warranted given its high prevalence and association with increased mortality and morbidity [10]. A close relationship between HRQoL and depression has been well established [11].
Although, it is already well known that CKD is associated with a decreased HRQoL, especially in dialysis populations [4], [12], [13], only recently, adult patients with glomerular disease were studied regarding their HRQoL [14]. Gipson et al. described these patients had a low HRQoL, comparable with dialysis patients [14]. However, this study population was a mix of children and adults with the same glomerular pathology (focal segmental glomerulosclerosis - FSGS) and they were studied at baseline during a therapeutic randomized trial. It was not possible to extrapolate the conclusions to other primary glomerulopathies and there is no information on treatment effects and factors associated with low HRQoL. Moreover, to the best of our knowledge, there is no data about depression in adult glomerulopathy patients.
The objective of the present study is to evaluate HRQoL and depression in a cohort of patients with a diagnosis of nephrotic syndrome-related primary glomerulopathy not undergoing chronic renal replacement therapy.
Methods
This is a cross-sectional study with patients presenting nephrotic syndrome at the time of a kidney biopsy in a reference university hospital of Brazil (Hospital Geral de Fortaleza). Nephrotic syndrome was defined as 24 h-urine protein greater than 3.5 g/1.73 m2 associated with edema, hypoalbuminemia (less than 3.0 g/dL) and lipid alteration. Only patients presenting primary minimal lesions (ML), FSGS, Membranous Nephropathy (MN), IgA nephropathy (IgAN) and membranoproliferative glomerulonephritis (MPGN) at kidney biopsy were considered. Patients with any evidence of secondary glomerulopathy or advanced CKD (GFR less than 15 mL/min/1.73 m2) were excluded.
Two age and sex-matched controls groups were selected: one consisting of patients undergoing maintenance hemodialysis for more than three months with no primary glomerulopathy diagnosis and another with healthy subjects. The study protocol was reviewed and approved by the Ethical Committee of the Institution (University of Fortaleza – UNIFOR) and informed consent was obtained from participants.
Measurements
Subjects underwent structured interviews during a research clinic visit. The interviews were used to obtain patient symptom checklist, medical comorbidities, sociodemographic characteristics, HRQoL and depression assessment. The Short Form-36 (SF-36) questionnaire was applied in the Portuguese version validated in Brazil [15]. This scale covers eight domains, four physical and four emotional ones. Each domain has a scale of 0 to 100, with a higher score always representing better HRQoL. These scales are aggregated into a physical composite score (PCS) and a mental composite score (MCS).
Depression was evaluated by the 17-item Hamilton depression Rating Scale (HAMD) also validated in Brazil [16]. The questionnaire was administered according to the Interview Guide for the Hamilton Rating Scale, of which purpose is to standardize the questions. The questionnaire has a scale that classifies degrees of depression according to these criteria: score lower than 6 – without mood swings/normal; from 7 to 17 – slightly depressed; from 18 to 24 – moderately depressed; above 25 – seriously depressed.
Treatment Protocol Summary
All patients were treated with angiotensin-converting enzyme inhibitors (ACE inhibitor) or AT1- receptor blocker (AT1R-blocker) when there was no contraindication. In ML and FSGS, the primary treatment was steroid-based therapy and cyclosporine (CsA) when it was steroid-resistant or dependent. MN was treated primarily with CsA or steroids plus cyclophosphamide according to baseline renal function. IgAN presenting with nephrotic syndrome was treated preferentially with steroids and MPGN patients received no immunosuppressive treatment.
Laboratory Data and Definitions
Medical records were retrieved to assess laboratory data at the kidney biopsy time and the last evaluation prior to study inclusion. Laboratory data included an assessment of serum creatinine, total blood count, serum albumin, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, 24 h-urine protein excretion rate (24 h-proteinuria) and urinalysis. Immunosuppressive treatment was considered only when it was taken for at least one month. Edema was considered when it was present in the last clinical evaluation. Hypertension was defined as blood pressure above 140×90 mmHg at three or more medical evaluation or a positive high blood pressure history under regular treatment. Hematuria was considered as more than five red blood cells per high-power microscopic field in two urine samples. Total remission was considered when 24 h-proteinuria was less than 500 mg and partial remission when there was a reduction greater than 50% of initial 24 h-proteinuria and it was less than 3.5 g/24 h/1.73 m2. Relapses were considered in patients presenting with 24 h-proteinuria greater than 3.5 g/24 h/1.73 m2 and serum albumin less than 3.0 g/dL after achieving partial or total remission. Frequent relapses were considered when there was more than 2 relapses in six months or 3 in a year. Estimated GFR (eGFR) was calculated using simplified MDRD equation. The local ethic's committee approved the study.
Statistical Analysis
Descriptive statistics are expressed as mean±SD or absolute numbers as appropriate. All variables were tested for normal distribution using the Kolmogorov-Smirnov test. One-way ANOVA with Bonferroni post-test or student's t-test was applied to compare means of continuous variables and normal distribution data. Categorical data were tested using the chi-square test.
Continuous estimated predictors of PCS, MCS and HAMD scores included: age, time of disease, body mass index (BMI), eGFR, 24 h-proteinuria at diagnosis, last 24 h-prot, hematocrit, last serum albumin, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides. Spearman's correlation coefficients (r s) were used to determine whether these estimated predictors correlated with PCS, MCS and HAMD scores.
Patients were categorized into groups based on gender, presence of diabetes mellitus, blood pressure status (normotensive versus hypertensive), use of ACE inhibitor or AT1R-blocker, statins, steroids, CsA, cyclophosphamide (yes vs. no for each drug class), presence of hematuria and remission status (total or partial vs. no-remission). Comparisons of PCS, MCS and HAMD scores between the abovementioned subgroups were performed using a two-sample t test.
Subsequent multiple linear regression modeling was used to determine which variables that were significant in the univariate analysis were independently associated with PCS, MCS and HAMD score. Models for PCS, MCS and HAMD scores were determined separately. Corresponding interaction terms were included in the initial model. Backwards elimination was performed, and variables (interaction terms and predictors) that were nonsignificant at the α = 0.05 level were sequentially removed from the model. Stepwise selection was also performed in an interactive manner, where variables with a p-value<0.10 were added to the model and variables with a p-value>0.05 were removed. The statistical analysis was performed using SPSS 19.0 for windows. p values<0.05 were considered as statistically significant.
Results
Population Characterization
From a group of 311 patients, 135 nephrotic-associated glomerulopathy patients were pre-selected and an interview was conducted in 99 glomerulopathy patients. Contact was not possible with other 36 patients. Mean age was 36±11 years old. Ninety-nine hemodialysis patients and healthy subjects age- and sex-matched were selected. Mean time of dialysis was 38±16 months.
Complete data on clinical and demographic characteristics of glomerulopathy patients are shown in table 1. Main histological diagnosis was FSGS (n = 49), MN (n = 29), ML (n = 4). Forty-three patients were receiving steroid drugs and nineteen received cyclosporine-based therapy. Patients undergoing steroid therapy were receiving a mean dose of 0.2 mg/Kg/day of prednisone. Thirty-eight patients were in total and 26 in partial remission. Thirty-five patients had achieved no remission. Twenty-six patients had had at least one relapse in the last three years before study entry and the mean of relapses frequency in these patients was 0.7/year. Only 3 patients were considered as having frequent relapses.
Table 1. Patients' clinical and demographic characteristics. Data are presented as mean±SD or absolute values.
| Glomerulopathy patients (n = 99) | |
| Age (years) | 36±11 |
| Gender (M/F) | 46/53 |
| Renal biopsy diagnosis | |
| FSGS | 49 |
| MN | 29 |
| IgAN | 9 |
| MPGN | 8 |
| ML | 4 |
| Disease duration (months) | 33.6±26.0 |
| Arterial Hypertension | 40 |
| Diabetes | 6 |
| Familial nephropathy history | 21 |
| Presence of edema | 31 |
| Mean eGFR (mL/min/1.73 m2) | 61±29 |
| CKD stage | |
| stage 1 | 55 |
| stage 2 | 24 |
| stage 3 | 16 |
| stage 4 | 04 |
| ACE inhibitor/AT1R blocker | 62 |
| Steroid therapy | 43 |
| Cyclosporine therapy | 19 |
| Cyclophosphamide therapy | 03 |
| Hemoglobin (g/dL) | 12.3±0.9 |
| Last serum albumin (g/dL) | 3.6±0.9 |
| Last total cholesterol (mg/dL) | 221±98 |
| Last triglycerides (mg/dL) | 146±58 |
| Proteinuria at diagnosis (g/24 h/1.73 m2) | 8.6±3.8 |
| Last proteinuria (g/24 h/1.73 m2) | 2.8±2.2 |
| Remission | |
| Total | 38 |
| Parcial | 26 |
| No | 35 |
FSGS: focal and segmentar glomerulosclerosis; ML: minimal lesions; MN: membranous Nephropathy; IgAN: IgA nephropathy; MPGN: membranoproliferative Glomerulonephritis; CKD: Chronic Kidney Disease; ACE: angiotensin converting enzyme; AT1R: angiotensin 1 receptor.
Quality of Life and Depression in Glomerulopathy Patients
Mean scores in each SF-36 domain in healthy, dialysis and glomerulopathy patients are shown in table 2. As expected, dialysis patients had a low score in all domains, when compared to healthy subjects, except in mental health. Glomerulopathy patients had low scores in all eight domains, when compared with healthy subjects. Glomerular patients had better scores at the physical functioning scale and worse mental health than hemodialysis patients. All other domains were similar between these two groups. Mental and physical health composite scores were lower in both dialysis and glomerulopathy patients than in healthy subjects was observed no difference between these two last groups.
Table 2. SF-36 HRQoL and HAMD comparison between glomerulopathy and hemodialysis patients and healthy subjects.
| Glomerulopathy patients (n = 99) | Hemodialysis patients (n = 99) | Healthy subjects (n = 99) | |
| Physical functioning scale # | 70.4±27.0 | 52.7±34.1 | 91.4±19.3 |
| Role, physical* | 37.9±22.5 | 26.7±20.9 | 87.0±31.2 |
| General Health* | 63.2±34.8 | 54.3±24.9 | 81.8±24.9 |
| Bodily pain* | 71.8±28.4 | 73.7±26.9 | 90.9±21.2 |
| Mental Health** | 66.5±22.6 | 78.3±19.8 | 78.4±18.4 |
| Role, emotional* | 57.4±36.22 | 70.0±35.4 | 97.3±14.8 |
| Vitality* | 62.2±22.1 | 63.1±26.5 | 73.7±19.1 |
| Social functioning* | 64.3±34.0 | 69.6±33.1 | 92.5±19.2 |
| Physical health composite score* | 61.6±21.1 | 56.6±21.4 | 85.7±14.9 |
| Mental health composite score* | 62.9±31.9 | 68.1±21.9 | 87.5±14.3 |
| Hamilton depression Rating Scale∂ | 8.3±6.9 | 7.0±5.7 | 5.1±4.1 |
#p<0.001 between all groups,
p<0.001 between healthy subjects and others groups,
p<0.01 between glomerulopathy patients and others groups,
p = 0.01 between glomerulopathy patients vs. healthy subjects.
Glomerulopathy patients were more depressed according to HAMD than healthy subjects (48 vs. 22.4%, p = 0.002) and were similar to dialysis patients (48 vs. 43%, p = 0.302). No patient was receiving depression therapy. Overall, glomerulopathy and dialysis patients had comparable HAMD scores (8.3±6.9 vs. 7.0±5.7, p = 0.613) and glomerulopathy patients had higher scores than healthy patients (5.1±4.1, p = 0.01) – see table 2. HAMD scores presented a significant inverse correlation with mental and physical health composite scores (r = −0.402 and −0.391, p<0.001 for both). There was no difference between patients according to histological diagnosis (data not shown).
Factors Associated with Quality of Life and Depression in Glomerulopathy Patients
Univariate analysis comparing the potential contributors to PCS, MCS and HAMD score were evaluated (tables 3 and 4). Using variables associated with each score, multiple regression analysis demonstrated that last 24 h-proteinuria and CsA use were associated with PCS; last 24 h-proteinuria was the only factor associated with MCS and gender, age, last 24 h-proteinuria and disease duration were independently associated with HAMD scores (table 5). Proteinuria at diagnosis (r s = −0.064, p = 0.532 with PCS; −0.016, p = 0.874 with MCS and 0.016, p = 0.888 with HAMD), eGFR (r s = 0.049, p = 0.613 with PCS; 0.078, p = 0.322 with MCS and 0.061, p = 0.496 with HAMD), mean daily prednisone dose in the last 6 months ((r s = −0.031, p = 0.723 with PCS; 0.012, p = 0.822 with MCS and 0.022, p = 0.896 with HAMD) and partial or total remission were not associated with any score evaluated.
Table 3. Scores in subgroups based on several clinical characteristics.
| Characteristic | Score | Score | p |
| Gender | Male (n = 46) | ||
| PCS | 64.3±19.7 | 0.225 | |
| MCS | 63.7±19.9 | 0.242 | |
| HAMD | 6.3±4.7 | 0.010 | |
| Hypertension | yes (n = 48) | no (n = 51) | |
| PCS | 58.4±20.3 | 63.2±21.0 | 0.302 |
| MCS | 58.9±19.4 | 61.7±22.3 | 0.568 |
| HAMD | 9.3±6.5 | 7.9±6.5 | 0.388 |
| Diabetes Mellitus | yes (n = 5) | no (n = 84) | |
| PCS | 56.4±17.3 | 61.6±21.0 | 0.589 |
| MCS | 64.9±16.6 | 60.3±21.4 | 0.641 |
| HAMD | 8.0±6.6 | b8.5±6.2 | 0.883 |
| ACE inhibitor/AT1R-blocker | yes (n = 68) | no (n = 31) | |
| PCS | 59.0±19.8 | 63.8±22.7 | 0.325 |
| MCS | 58.8±20.6 | 63.4±21.8 | 0.352 |
| HAMD | 8.3±6.5 | 8.7±6.3 | 0.844 |
| Statin | yes (n = 21) | no (n = 78) | |
| PCS | 54.6±21.4 | 63.1±20.4 | 0.084 |
| MCS | 56.4±21.1 | 62.0±21.0 | 0.298 |
| HAMD | 8.3±6.3 | 8.6±5.8 | 0.891 |
| Steroid therapy | Yes (n = 66) | no (n = 33) | |
| PCS | 58.0±18.9 | 62.8±22.16 | 0.310 |
| MCS | 58.9±20.12 | 61.7±21.8 | 0.562 |
| HAMD | 7.2±6.1 | 9.3±7.7 | 0.093 |
| CsA therapy | yes (n = 19) | no (n = 80) | |
| PCS | 53.8±17.8 | 62.2±21.3 | 0.035 |
| MCS | 51.9±19.8 | 62.2±21.0 | 0.045 |
| HAMD | 10.4±8.9 | 8.1±6.9 | 0.203 |
| Cyclophosphamide therapy | yes (n = 6) | no (n = 93) | |
| PCS | 54.7±12.9 | 61.1±21.4 | 0.552 |
| MCS | 65.6±17.2 | 60.4±21.4 | 0.634 |
| HAMD | 6.2±5.2 | 8.8±6.9 | 0.321 |
| Hematuria | yes (n = 27) | no (n = 72) | |
| PCS | 55.2±17.4 | 65.4±21.7 | 0.042 |
| MCS | 56.2±21.6 | 65.2±19,7 | 0.071 |
| HAMD | 7.5±6.1 | 8.4±6.2 | 0.590 |
| Remission | yes (n = 64) | no (n = 35) | |
| PCS | 61.5±19.9 | 60.7±27.2 | 0.906 |
| MCS | 61.7±19.1 | 61.4±27.7 | 0.961 |
| HAMD | 8.6±6.6 | 7.9±6.2 | 0.477 |
| Relapses at last three years | yes (n = 26) | no (n = 73) | |
| PCS | 59.7±16.8 | 61.7±19.6 | 0.771 |
| MCS | 60.3±18.0 | 62.0±21.6 | 0.693 |
| HAMD | 8.2±6.2 | 8.4±6.2 | 0.931 |
PCS: SF-36 Physical composite score; MCS: SF-36 Mental composite score; HAMD: Hamilton Depression Rating Scale; CsA: cyclosporine.
Table 4. Significant correlations (r s) between PCS, MCS and HAMD score with clinical and laboratory data.
| Physical Composite Score | p | Mental Composite Score | p | HAMD Score | p | |
| Age (years) | - | - | - | - | 0.200 | 0.034 |
| Disease duration (months) | - | - | - | - | 0.400 | 0.001 |
| Last 24 h-proteinuria (mg) | −0.233 | 0.024 | −0.237 | 0.019 | 0.223 | 0.029 |
| Last cholesterol, total (mg/dL) | - | - | −0.208 | 0.029 | 0.250 | 0.012 |
Table 5. Variables independently associated with PCS, MCS and HAMD score.
| Physical Composite Score | |||
| Variable | B | 95%CI for B | p |
| Last 24 h-proteinuria (g/24 h) | −0.182 | −0.223 to −0.710 | 0.01 |
| CsA use | −15.315 | −25.913 to −2.717 | 0.03 |
Discussion
In this study, adult glomerulopathy patients had worse HRQoL and high depression prevalence and severity than healthy subjects, being comparable with patients on maintenance hemodialysis. Moreover, we determined that actual proteinuria was associated with HRQoL and depression.
Glomerulopathy patients have several characteristics that can affect quality of life. Presence of severe edema, loss of renal function, daily activities and diet restriction can potentially reduce physical and mental aspects of quality of life. Moreover, treatment-related adverse effects can be associated with poor quality of life. However, only recently it has been reported that FSGS patients with no treatment had low HRQoL scores [14], but there is no information about the factors associated with this low HRQoL and if reduction-proteinuria treatment has any impact on its improvement. Moreover, depression was never studied in glomerulopathy patients before.
It is known that advanced CKD patients have poor HRQoL and severe depression diagnosis, whether they are undergoing or not renal replacement therapy. [13], [17]–[19] In our data, glomerulopathy patients had low HRQoL and depression, comparable to hemodialysis patients. Of eight SF-36 domains, six showed similar scores between glomerulopathy and hemodialysis patients. Only functional capacity was worse in hemodialysis patients; similar findings were observed by Gipson et al. [14], when evaluating FSGS patients. Although HRQoL in hemodialysis patients is extensively described in literature [4], we prefer to reassess these data with an age- and sex-matched group, due to possible regional differences when comparing reports from developed countries.
Abdel-Kader et al. described patients with stage 4 and 5 CKD that had comparably low HRQoL and depression [19]; however, our cohort had a mean eGFR of 61±29 mL/min/1.73 m2 and only six patients had stage 4 CKD. It is unlikely that low HRQoL and depression burden in glomerulopathy patients be due only to a reduced eGFR.
Only three populations with glomerulopathy have been studied regarding HRQoL: pediatric patients with steroid-sensitive nephrotic syndrome [20], children and adults with untreated FSGS [14]. These studies have demonstrated a low HRQoL in nephrotic patients. Our data includes several histological glomerulopathies types. This is important in data validation and because different features of the glomerulopathy type (remission index and CKD evolution) can have different impacts on HRQoL.
To the best of our knowledge, depression has not been assessed in glomerulopathy patients. In this study, glomerulopathy patients had higher HAMD score than healthy subject and were comparable to hemodialysis patients. In the general population, prevalence of depression in women ranges from 5 to 9% and 2 to 3% in men [5]. It is important to distinguish between the diagnosis of major depressive disorder and the symptoms of depression [9], with the first being evaluated by DSM-IV [21]. HAMD is used as an instrument to screen for depression, so it is not possible to estimate the true prevalence of depression in the studied population. In spite of these considerations, glomerulopathy patients presented high HAMD scores and depression must be assessed by a physician in this population.
It is unknown if glomerulopathy-directed treatment can ameliorates HRQoL and depressive symptoms. An ongoing randomized clinical trial is using HRQoL as an end-point in FSGS patients [14]. In our sample, patients achieving partial or total remission had comparable scores for both HRQoL and HAMD when compared with those not achieving remission. However, the presence of 24 h-proteinuria was independently associated with PCS, MCS and HAMD score. These data suggest that proteinuria reduction, even when not sufficient to be classified as remission, can be important in order to improve HRQoL and depression symptoms. This is important because using remission criteria when evaluating HRQoL and depression in glomerulopathy patients can be inaccurate.
It is not possible to determine the pathophysiological background of the association between proteinuria and quality of life and depression. It is possible that subjective factors such as concerns about disease control and prognosis may interfere directly in the assessment of HRQoL. Also, patients with higher proteinuria levels have more dietary and physical activity restrictions. Moreover, proteinuria is associated with inflammation [22]. In other medical conditions [23], [24], inflammation has been associated with depression and HRQoL, suggesting that future studies must explore this possible relationship.
Cyclosporine use was associated with low PCS. This information is dissimilar from other data in renal transplantation [25], where steroid-therapy is associated with low physical performance. In our study, less than half of the patients were receiving steroid therapy (n = 43), with a mean dose of 0.2 mg/Kg/day. In glomerulopathy, steroid therapy is generally limited to a six-month course and steroid-resistant or dependent patients are generally changed to CsA-based therapy. This short-term of steroid therapy, in contrast with other clinical conditions, i.e. renal transplantation, can explain the absence of association between steroid dose and HRQoL and HAMD scores.
In our patients, cyclosporine was used as primary choice in MN and in steroid-resistant or dependent FSGS and ML. Generally, these patients maintain CsA use for one year after achieving remission, in contrast with steroid-treated patients that generally undergo a 4 to 6 month-duration therapy. We speculate this long-course CsA therapy can adversely affect the physical component. Moreover, two patients receiving CsA had moderate/severe depressive symptoms. Depression has been associated with CsA therapy [26] and it is reversible after its withdrawal. Although no data was available about depression diagnosis before CsA initiation in our patients, CsA must be considered as having an etiological role.
Disease duration and age were associated with depression. It is known that many chronic medical conditions can impair HRQoL and increase depression prevalence [7], [27]. It is known there is a higher prevalence of depression in older subjects [28]. As in other chronic diseases [29], [30], in this sample disease duration was also associated with depression symptoms.
Renal function and protein excretion rate at diagnosis were not associated with any score. The first can be explained due to high eGFR in our sample, where 60% had only mild CKD (eGFR>60 mL/min/1.73 m2). The lack of association between 24 h-proteinuria at diagnosis and the association with the present one highlights the importance of proteinuria reduction in ameliorating HRQoL and depression.
Our study has several limitations. First, it was performed in a developing country. The results can be different in developed countries. In the present study, we evaluated a relatively small number of hemodialysis patients, but our data is comparable with those in literature [14], making this a valid control group. Moreover control groups were age- and sex-matched. Lastly, we cannot explain the exact mechanism of the association between 24 h-proteinuria and HRQoL and depression.
In conclusion, adult nephrotic syndrome-related glomerulopathy patients had low HRQoL and high depression symptom scores. These were comparable with those in hemodialysis patients. Presence of proteinuria was associated with worse HRQoL and depression. We suggest that classical cutoff points of urine protein excretion to classify remission are not sensitive to evaluate amelioration in HRQoL and depression symptoms.
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: No current external funding sources for this study.
References
- 1.Malafronte P, Mastroianni-Kirsztajn G, Betônico GN, Romão JE, Alves MA, et al. Paulista Registry of glomerulonephritis: 5-year data report. Nephrol Dial Transplant. 2006;21:3098–3105. doi: 10.1093/ndt/gfl237. [DOI] [PubMed] [Google Scholar]
- 2.Mazairac AH, de Wit GA, Penne LE, van der Weerd NC, Grooteman MP, et al. Protein-Energy Nutritional Status and Kidney Disease-specific Quality of Life in Hemodialysis Patients. J Ren Nutr. 2010. [DOI] [PubMed]
- 3.Miettola J, Niskanen LK, Viinamäki H, Sintonen H, Kumpusalo E. Metabolic syndrome is associated with impaired health-related quality of life: Lapinlahti 2005 study. Qual Life Res. 2008;17:1055–1062. doi: 10.1007/s11136-008-9386-6. [DOI] [PubMed] [Google Scholar]
- 4.Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45:658–666. doi: 10.1053/j.ajkd.2004.12.021. [DOI] [PubMed] [Google Scholar]
- 5.Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 2000;132:738–742. doi: 10.7326/0003-4819-132-9-200005020-00010. [DOI] [PubMed] [Google Scholar]
- 6.Simon GE. Treating depression in patients with chronic disease: recognition and treatment are crucial; depression worsens the course of a chronic illness. West J Med. 2001;175:292–293. doi: 10.1136/ewjm.175.5.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Omachi TA, Katz PP, Yelin EH, Gregorich SE, Iribarren C, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med. 2009;122:778.e9–778.15. doi: 10.1016/j.amjmed.2009.01.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Saveanu RV, Mayes T. Diagnosing depression in congestive heart failure. Heart Fail Clin. 2011;7:75–79. doi: 10.1016/j.hfc.2010.08.010. [DOI] [PubMed] [Google Scholar]
- 9.Cohen SD, Norris L, Acquaviva K, Peterson RA, Kimmel PL. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2007;2:1332–1342. doi: 10.2215/CJN.03951106. [DOI] [PubMed] [Google Scholar]
- 10.Kimmel PL, Peterson RA. Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived? Clin J Am Soc Nephrol. 2006;1:349–352. doi: 10.2215/CJN.00890306. [DOI] [PubMed] [Google Scholar]
- 11.Kennedy SH, Eisfeld BS, Cooke RG. Quality of life: an important dimension in assessing the treatment of depression? J Psychiatry Neurosci. 2001;26(Suppl):S23–S28. [PMC free article] [PubMed] [Google Scholar]
- 12.Gokal R. Quality of life in patients undergoing renal replacement therapy. Kidney Int. 1993;Suppl 40:S23–S27. [PubMed] [Google Scholar]
- 13.Finkelstein FO, Wuerth D, Finkelstein SH. Health related quality of life and the CKD patient: challenges for the nephrology community. Kidney Int. 2009;76:946–952. doi: 10.1038/ki.2009.307. [DOI] [PubMed] [Google Scholar]
- 14.Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, et al. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int. 2011;79:678–685. doi: 10.1038/ki.2010.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Aguiar CC, Vieira AP, Carvalho AF, Montenegro-Junior RM. [Assessment instruments for a Health-Related Quality of Life in diabetes mellitus]. Arq Bras Endocrinol Metabol. 2008;52:931–939. doi: 10.1590/s0004-27302008000600004. [DOI] [PubMed] [Google Scholar]
- 16.Fleck MP, Chaves ML, Poirier-Littré MF, Bourdel MC, Loo H, et al. Depression in France and Brazil: factorial structure of the 17-item Hamilton Depression Scale in inpatients. J Nerv Ment Dis. 2004;192:103–110. doi: 10.1097/01.nmd.0000110281.35970.33. [DOI] [PubMed] [Google Scholar]
- 17.Valderrábano F, Jofre R, López-Gómez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001;38:443–464. doi: 10.1053/ajkd.2001.26824. [DOI] [PubMed] [Google Scholar]
- 18.Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis. 2000;35:629–637. doi: 10.1016/s0272-6386(00)70009-6. [DOI] [PubMed] [Google Scholar]
- 19.Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4:1057–1064. doi: 10.2215/CJN.00430109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Rüth EM, Landolt MA, Neuhaus TJ, Kemper MJ. Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr. 2004;145:778–783. doi: 10.1016/j.jpeds.2004.08.022. [DOI] [PubMed] [Google Scholar]
- 21.American Psychiatric Association: Diagnosis and Statistical of Mental Disorders, 4th Ed. Washington, D.C.: American Psychiatric Association; 1994. [Google Scholar]
- 22.Dogra GK, Herrmann S, Irish AB, Thomas MA, Watts GF. Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial Transplant. 2002;17:2220–2225. doi: 10.1093/ndt/17.12.2220. [DOI] [PubMed] [Google Scholar]
- 23.Farag YM, Keithi-Reddy SR, Mittal BV, Surana SP, Addabbo F, et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients. Clin Nephrol. 2011;75:524–533. doi: 10.5414/cnp75524. [DOI] [PubMed] [Google Scholar]
- 24.Kalender B, Ozdemir AC, Koroglu G. Association of depression with markers of nutrition and inflammation in chronic kidney disease and end-stage renal disease. Nephron Clin Pract. 2006;102:c115–c121. doi: 10.1159/000089669. [DOI] [PubMed] [Google Scholar]
- 25.Painter PL, Topp KS, Krasnoff JB, Adey D, Strasner A, et al. Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients. Kidney Int. 2003;63:2309–2316. doi: 10.1046/j.1523-1755.2003.00038.x. [DOI] [PubMed] [Google Scholar]
- 26.Zhu WL, Shi HS, Wang SJ, Wu P, Ding ZB, Lu L. Hippocampal CA3 calcineurin activity participates in depressive-like behavior in rats. J Neurochem. 2011;117:1075–1086. doi: 10.1111/j.1471-4159.2011.07285.x. [DOI] [PubMed] [Google Scholar]
- 27.Faller H, Störk S, Schuler M, Schowalter M, Steinbüchel T, et al. Depression and disease severity as predictors of health-related quality of life in patients with chronic heart failure–a structural equation modeling approach. J Card Fail. 2009;15:286–292.e2. doi: 10.1016/j.cardfail.2008.10.022. [DOI] [PubMed] [Google Scholar]
- 28.Unützer J. Clinical practice. Late-life depression. N Engl J Med. 2007;357:2269–2276. doi: 10.1056/NEJMcp073754. [DOI] [PubMed] [Google Scholar]
- 29.Taner E, Coşar B, Burhanoğlu S, Calikoğlu E, Onder M, Arikan Z. Depression and anxiety in patients with Behçet's disease compared with that in patients with psoriasis. Int J Dermatol. 2007;46:1118–1124. doi: 10.1111/j.1365-4632.2007.03247.x. [DOI] [PubMed] [Google Scholar]
- 30.Almawi W, Tamim H, Al-Sayed N, Arekat MR, Al-Khateeb GM, et al. Association of comorbid depression, anxiety, and stress disorders with Type 2 diabetes in Bahrain, a country with a very high prevalence of Type 2 diabetes. J Endocrinol Invest. 2008;31:1020–1024. doi: 10.1007/BF03345642. [DOI] [PubMed] [Google Scholar]